Shimada A, Kawasaki E, Abiru N, et al. Diagnostic Criteria of SPIDDM (2023). J Japan Diabetes Soc. 2023;66:587–91 ((In Japanese)).

Google Scholar 

Shimada A, Kawasaki E, Abiru N, et al. New diagnostic criteria (2023) for slowly progressive type 1 diabetes (SPIDDM): Report from Committee on Type 1 Diabetes in Japan Diabetes Society (English version). Diabetol Int. 2024;15:1–4.

Article  PubMed  Google Scholar 

Shimada A, Kawasaki E, Abiru N, et al. New diagnostic criteria (2023) for slowly progressive type 1 diabetes (SPIDDM): Report from Committee on Type 1 Diabetes of the Japan Diabetes Society (English version). J Diabetes Investig. 2024;15:254–7.

Article  PubMed  PubMed Central  Google Scholar 

Tanaka S, Ohmori M, Awata T, et al. Diagnostic criteria for slowly progressive insulin-dependent (type 1) diabetes mellitus (SPIDDM) (2012): report by the Committee on Slowly Progressive Insulin-Dependent (Type 1) Diabetes Mellitus of the Japan Diabetes Society. Diabetol Int. 2015;6:1–7.

Article  Google Scholar 

Nishimura A, Matsumura K, Kikuno S, et al. Slowly Progressive Type 1 Diabetes Mellitus: Current Knowledge And Future Perspectives. Diabetes Metab Syndr Obes. 2019;12:2461–77.

Article  PubMed  PubMed Central  Google Scholar 

Yasui J, Kawasaki E, Tanaka S, et al. Japan Diabetes Society Committee on Type 1 Diabetes Mellitus Research. Clinical and Genetic Characteristics of Non-Insulin- Requiring Glutamic Acid Decarboxylase (GAD) Autoantibody-Positive Diabetes: A Nationwide Survey in Japan. PLoS ONE. 2016;11:e0155643.

Article  PubMed  PubMed Central  Google Scholar 

Tanaka S, Awata T, Shimada A, et al. Clinical Characteristics of Slowly Progressive Insulin-Dependent (Type 1) Diabetes Mellitus (SPIDDM: 1st Subcommittee Report on SPIDDM, Committee on Type 1 Diabetes, Japan Diabetes Society and Committee on Type 1 Diabetes. J Japan Diab Soc. 2011;54:65–75 ((In Japanese)).

Google Scholar 

Kawasaki E. Anti-islet autoantibodies in type 1 diabetes. Int J Mol Sci. 2023;24:10012.

Article  PubMed  PubMed Central  Google Scholar 

Maruyama T, Tanaka S, Shimada A, et al. Insulin interven slowly J Clin Endocrinol Metab. 2008;93:2115–21.

Article  Google Scholar 

Buzzetti R, Tuomi T, Mauricio D, et al. Management of Latent Autoimmune Diabetes in Adults: A Consensus Statement. From Int Expert Panel Diabetes. 2020;69:2037–47.

Google Scholar 

Zachariah S, Sharfi MO, Nussey SS, et al. Latent autoimmune diabetes in the young. Clin Med (Lond). 2008;8:552–3.

Article  PubMed  Google Scholar 

Kawasaki E, Nakamura K, Kuriya G, et al. Autoantibodies to insulin, insulinoma-associated antigen-2, and zinc transporter 8 improve the prediction of early insulin requirement in adult-onset autoimmune diabetes. J Clin Endocrinol Metab. 2010;95:707–13.

Article  PubMed  Google Scholar 

Murao S, Kondo S, Ohashi J, et al. Anti-thyroid peroxidase antibody, IA-2 antibody, and fasting C-peptide levels predict beta cell failure in patients with latent autoimmune diabetes in adults (LADA)–a 5-year follow-up of the Ehime study. Diabetes Res Clin Pract. 2008;80:114–21.

Article  PubMed  Google Scholar 

Tanaka S, Okubo M, Nagasawa K, et al. Predictive value of titer of GAD antibodies for further progression of beta cell dysfunction in slowly progressive insulin-dependent (type 1) diabetes (SPIDDM). Diabetol Int. 2015;7:42–52.

Article  PubMed  PubMed Central  Google Scholar 

Wada E, Onoue T, Kinoshita T, et al. Adult-onset autoimmune diabetes identified by glutamic acid decarboxylase autoantibodies: a retrospective cohort study. Diabetologia. 2021;64:2183–92.

Article  PubMed  Google Scholar 

Turner R, Stratton I, Horton V, et al. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospect Diabetes Study Group Lancet. 1997;350(9087):1288–93.

Google Scholar 

Johansen OE, Boehm BO, Grill V, et al. C-peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: exploratory results from a 2-year double-blind, randomized, controlled study. Diabetes Care. 2014;37:e11-12.

Article  PubMed  Google Scholar 

Awata T, Shimada A, Maruyama T, et al. Possible Long-Term Efficacy of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, for Slowly Progressive Type 1 Diabetes (SPIDDM) in the Stage of Non- Insulin-Dependency: An Open-Label Randomized Controlled Pilot Trial (SPAN-S). Diabetes Ther. 2017;8:1123–34.

Article  PubMed  PubMed Central  Google Scholar 

Zhao Y, Yang L, Xiang Y, et al. Dipeptidyl peptidase 4 inhibitor sitagliptin maintains beta-cell function in patients with recent-onset latent autoimmune diabetes in adults: a one year prospective study. J Clin Endocrinol Metab. 2014;99:E876-880.

Article  PubMed  Google Scholar 

Kim SJ, Nian C, McIntosh CH. Sitagliptin (MK0431) inhibition of dipeptidyl peptidase IV decreases nonobese diabetic mouse CD4+ T-cell migration. Diabetes. 2010;59:1739–50.

Article  PubMed  PubMed Central  Google Scholar 

Tian L, Gao J, Hao J, et al. Reversal of new-onset diabetes through modulating inflammation and stimulating beta-cell replication in nonobese diabetic mice by a dipeptidylpeptidase IV inhibitor. Endocrinology. 2010;151:3049–60.

Article  PubMed  Google Scholar 

Shimada A, Shigihara T, Okubo Y, et al. Pioglitazone may accelerate the disease course of slowly progressive type 1 diabetes. Diabetes Metab Res Rev. 2011;27:951–3.

Article  PubMed  Google Scholar 

Ursini F, Russo E, Pellino G, et al. Metformin and Autoimmunity: A “New Deal” of an Old Drug. Front Immunol. 2018;9:1236.

Article  PubMed  PubMed Central  Google Scholar 

Maganti AV, Tersey SA, Syed F, et al. Peroxisome Proliferator-activated Receptor-γ Activation Augments the β-Cell Unfolded Protein Response and Rescues Early Glycemic Deterioration and β-Cell Death in Non-obese Diabetic Mice. J Biol Chem. 2016;291(43):22524–33.

Article  PubMed  PubMed Central  Google Scholar 

Shigihara T, Okubo Y, Kanazawa Y, et al. Thiazolidinediones may not reduce diabetes incidence in type 1 diabetes. Ann N Y Acad Sci. 2006;1079:365–8.

Article  PubMed  Google Scholar 

Zhou Z, Li X, Huang G, et al. Rosiglitazone combined with insulin preserves islet beta cell function in adult-onset latent autoimmune diabetes (LADA). Diabetes Metab Res Rev. 2005;21:203–8.

Article  PubMed  Google Scholar 

Pozzilli P, Leslie RD, Peters AL, et al. Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): a post-hoc analysis of the AWARD-2, -4 and -5 Trials. Diabetes Obes Metab. 2018;20:1490–8.

Article  PubMed  Google Scholar 

Shimada A, Kawasaki E, Abiru N, et al. Statement regarding treatment for suspected slowly progressive type 1 diabetes cases. J Japan Diabetes Soc. 2023;66:807–14 ((In Japanese)).

Google Scholar